Sum-191

Preclinical

SSenju USA, Inc.

Sum-191 is one of 18 therapeutic programs targeting Bacterial Conjunctivitis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Bacterial ConjunctivitisRecruiting

Bacterial ConjunctivitisPreclinical

Recruiting

Competition

Competitive Landscape

37 competitors in Bacterial Conjunctivitis

#DrugCompanyPhaseTrials

Vancocin

HHikma Pharmaceuticals LLC

Levaquin

Avelox

1 4

Tobrex

VViatris Specialty LLC

Phase 3

2 5

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 6

Zymar

AbbVie

Phase 3

2 7

Vigamox

Merck & Co.

Approved

3 8

Besivance

BBausch Health Americas, Inc.

Phase 3

3 9

Azasite

Merck & Co.

Phase 3

2 10

SHP640

Takeda

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

PreclinicalRecruiting

Bacterial Conjunctivitis

NCT07565103

Clinical

Trials by Indication[1]

Bacterial Conjunctivitis1 trial

A Phase I/II Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of SUM-191 in Healthy Participants and in Participants With Bacterial Conjunctivitis

Recruiting·SSenju USA, Inc.·Preclinical·NCT07565103·426 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sum-191. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Sum-191. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Senju USA, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: SSenju USA, Inc.

Sum-191

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Bacterial Conjunctivitis1 trial

References

Drug Info

Quick Facts

Related News